



Uppsala, Sweden, 2009-08-25

## PRESS RELEASE

### **Oasmia S.A.'s commitment to subscribe for shares in Oasmia Pharmaceutical AB's (publ) rights issue**

Oasmia S.A. (the "Principal Owner") has committed to subscribe for its share of Oasmia Pharmaceutical AB's (publ) ("Oasmia") rights issue (the "Rights issue"), i.e. 70.2 percent of the total volume or 1,680,490 shares, corresponding to approximately SEK 42.0 million. The Principal Owner's holding of shares in Oasmia is separated into two blocks, through which the total subscription commitment of SEK 42.0 million is divided in SEK 12.6 million and SEK 29.4 million per block respectively.

The subscription rights relating to the subscription commitment of SEK 12.6 million have, by mistake, been sold in the market by the Principal Owner's bank. Hence, the Principal Owner did not, at the end of the subscription period on 24 August 2009, own these subscription rights and could, as a consequence, not fully fulfill its commitment to subscribe for shares.

The Principal Owner has taken the following measure to ascertain that Oasmia will not be financially worse off than if the SEK 12.6 million subscription commitment would have been possible to fulfill:

- The Principal Owner has applied for subscription of shares in the amount of SEK 12.6 million without exercise of subscription rights in addition to subscribing for shares in the amount of SEK 29.4 million through exercise of subscription rights. The subscription amount of SEK 12.6 million without exercise of subscription rights corresponds to the subscription that would have been made if some of the subscription rights would not have been sold.

The Principal Owner believes that this measure should compensate for any possible negative effects resulting from the Principal Owner's inability to fully fulfill its subscription commitment.

In addition to the above, and at the same time, the Principal Owner has decided to put a credit facility of SEK 30.0 million at Oasmia's disposal. The credit facility is available as from today's date and it can be claimed at any time by Oasmia. The initial time to maturity is twelve months and the interest rate is five per cent.

## **About Oasmia**

Oasmia Pharmaceutical AB develops second and third generation cancer drugs based on nanotechnology for human and veterinary use. The broad portfolio is focused on oncology and contains several promising products in clinical and pre-clinical phase. Oasmia cooperates with leading universities and other biotech companies to discover and optimize substances with a favourable safety profile and better efficacy. The company name was registered in 1999 and is based in Uppsala, Sweden.

---

For more information, please contact: Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB.  
E-mail: [press@oasmia.com](mailto:press@oasmia.com) Phone: +46 (0) 18 50 54 40. Information is also available at [www.ngm.se](http://www.ngm.se) and [www.oasmia.com](http://www.oasmia.com)